CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that the Humanitarian Foundation Swiss Red Cross has granted funds to Swiss Tranfusion SRC (Blutspende SRK Schweiz) to adapt the INTERCEPT Blood System for red blood cells for pathogen inactivation and transfusion of whole blood, specifically for sub-Saharan African countries. The initial funding of 1.5 million Swiss Francs will support the feasibility phase of the project and completion of in vitro studies to support patient clinical trials.
Help employers find you! Check out all the jobs and post your resume.
